Wockhardt shares jump over 4%, extend two-day rally following FDA nod for Zaynich
[hfe_template id='11223']
[ad_1]
Wockhardt Ltd shares rose more than 4% to Rs 1,533 in Wednesday trading, extending a two-day rally after the stock surged nearly 20% on Tuesday. The momentum follows a landmark announcement from the company: the US Food and Drug Administration (FDA) has formally accepted its New Drug Application (NDA) for Zaynich, a first-in-class antibiotic developed by Wockhardt. The NDA, originally filed on September 30, 2025, marks the first time an Indian pharmaceutical company has had an NDA for a New Chemical Entity accepted by the US FDA—a historic moment for the company. The company highlighted that the acceptance underscores one of the most rigorous scientific and regulatory validations in global drug development, involving comprehensive clinical data, advanced manufacturing standards, and strict compliance requirements. Zaynich, which has been granted Fast Track designation, is now set for priority review by the US FDA. The antibiotic works on ...